Extended Data Fig. 3: Immune correlates between TMB-high and TMB-low cancers using the earliest cutoff at which ICIs are predictive.

PD-L1 positive cell frequency, T-cell inflammatory score, and CD8 + T cell frequency are compared between TMB-high cancers and TMB-low cancers using the earliest cutoff at which ICIs are associated with OS benefit. Biomarkers enriched in TMB-high and TMB-low cancers using a false discovery rate of 0.05 are highlighted.